skip to Main Content

UTEST’s co-directors share what makes for a great start-up application

utestThe University of Toronto Early-Stage Technology (UTEST) program helps U of T students, recent grads or professors to take their ideas to market.

Successful applicants get mentoring, funding and work space over a 12-month period as they advance their ideas. The program is co-managed by MaRS Innovation and the University of Toronto.

In a U of T “Spotlight on Startups” news article, Brianna Goldberg spoke with Mike Betts and Kurtis Scissons, UTEST co-directors, on what makes for a great applicant.

Here’s an excerpt:

What are you looking for in an exceptional UTEST application?
Evidence of a strong and committed team.  It’s critical to have standout technology and a great market opportunity but at the end of the day it’s the team that makes these businesses work—it’s about having a balance of amazing technical talent and business leadership and execution skills. When we come across an application that has a really awesome team, it stands out. – Mike Betts, UTEST co-director

What’s one common mistake you see in applications for UTEST that might cause them to be rejected?
Commitment. We want entrepreneurs that are fully committed to the program and to their new companies. UTEST is a serious program for serious entrepreneurs who want support to create a sustainable successful company. The application must exude your confidence in your idea and the effort the entrepreneur(s) will commit to see it successful.  Kurtis Scissons, UTEST co-director

What advice would you give to those considering applying to UTEST?
1. Build a balanced team. Understand the strengths of your team members and ensure that gaps can be addressed either through internal change or be open to external hires.

2. Be passionate about your idea but also understand it will be a rollercoaster of emotions. –Scissons

Betts and Scissons are accepting applications for UTEST’s third cohort until April 17. Current students, current faculty and recent graduates of U of T are welcome to apply.

Continue Reading

Council of Academic Hospitals features WaveCheck technology and crowdfunding campaign

waveThe Council of Academic Hospitals of Ontario’s online magazine highlighted WaveCheck on February 3, 2014 as a more personalized approach to cancer treatments because of the technology’s ability to effectively monitor chemotherapy response.

WaveCheck’s technology, invented by Dr. Gregory Czarnota of Sunnybrook Health Sciences Centre and Professor Michael C. Kolios of Ryerson University, allows women and men undergoing chemotherapy for breast cancer to know if their treatment is working at the beginning of treatment (within one to four weeks) rather than at the end of treatment (typically four to six months).

Here’s an excerpt from the article:

Breast cancer is the most common cancer among Canadian women, excluding non-melanoma skin cancers. It is the second leading cause of death from cancer in women in this country. The Canadian Cancer Society estimated that, in 2013, 65 Canadian women would be diagnosed with breast cancer every day, totaling 23,800 women a year; and 14 Canadian women would die from breast cancer every day, totaling 5,000 women a year. According to the Canadian Breast Cancer Foundation, one in nine Canadian women is expected to develop breast cancer during her lifetime; one in 29 will die from it.

Continue Reading

Johnson & Johnson Innovation Announces Collaborations with Two Canadian Early-Stage Drug Technology Development Centers

The commercialization process: Moving transformational ideas from the lab bench to the street
MaRS Innovation’s commercialization process helps inventors move their transformational ideas from the lab bench to the market.

Johnson & Johnson Innovation and its affiliate Janssen Inc. in Canada announced new collaborations with two Canadian early-stage drug technology development centres, Montreal-based NEOMED and Toronto-based MaRS Innovation, to identify and advance promising bio/pharmaceutical technologies that have the potential to impact human health.

Read the original release via The National Post or in French. MaRS Innovation’s November 25 announcement about the partnership is also available.

This story was covered by GEN: Genetic Engineering Biotechnology News.

Through these collaborations, technical experts from the Johnson & Johnson Innovation Center in Boston, Massachusetts will work with NEOMED and MaRS Innovation to identify investment opportunities emerging from well-validated scientific research discoveries within their communities of academic institutions and biotechnology companies.

Continue Reading

MaRS Innovation President and CEO Named to Ontario Health Innovation Council

Council members include MI’s Raphael Hofstein and MI Board Chair Dr. Robert Bell

On November 20, the Government of Ontario launched the Ontario Health Innovation Council to support health innovation in Ontario. Dr. Raphael Hofstein, president and CEO of MaRS Innovation, was named to the council.

Screen Shot 2013-12-18 at 4.33.09 PM
Members of the Ontario Health Innovation Council, including MaRS Innovation’s president and CEO Dr. Raphael Hofstein (third from left), pose after the initial announcement.

By becoming a member of the Council, Hofstein will assist in identifying evidence-based opportunities in Ontario’s healthcare space and advancing them into practice on a global scale.

Continue Reading
Back To Top